SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
Conclusion: SGLT2 inhibitors are novel antidiabetic medications with immense utility in the management of patients with T2DM. Furthermore, SGLT2 inhibitors have demonstrated to reduce the progression to advanced forms of kidney disease and its associated complications. These medications should be front and center in the management of patients with diabetic kidney disease with and without chronic kidney disease as they confer protection against cardiovascular/renal death and improve all-cause mortality. Future studies should evaluate the benefits and implications of early initiation of SGLT2 inhibitors, as well as the long-term effects of this therapy.
PMID: 33149657 [PubMed]
Source: International Journal of Nephrology and Renovascular Disease - Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
More News: Alternative and Complementary Therapies | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Forxiga | Heart | Heart Attack | Heart Disease | Heart Failure | Insulin | Proteinuria | SGLT2 Inhibitors | Sodium | Stroke | Study | Urology & Nephrology | Weight Loss